Recombinant Human Insulin-like Growth Factor-Binding Protein 7 (Human IGF-BP7)_C230376

Description

IGF-BPs control the distribution, function and activity of IGFs in various cell tissues and body fluids. Currently, there are seven named IGF-BPs that form high affinity complexes with both IGF-I and IGF-II. IGF-BP7 is expressed in a wide range of normal human tissues, and it generally shows reduced expression in cancer cell lines of prostate, breast, colon, and lung origin.  It plays a  role in skeletal myogenesis by binding to IGF in a manner that inhibits IGF-induced differentiation of skeletal myoblasts, without affecting IGF-induced proliferation. Additionally, IGF-BP7 suppresses growth and colony formation of prostate and breast  cancer cell lines through an IGF-independent mechanism, which causes a delay in the G1 phase of the cell cycle and increased apoptosis. Recombinant Human IGF-BP7 is a 26.4 kDa protein consisting of 256 amino acid residues.

 

Product Properties

Synonyms

Insulin-like Growth Factor-Binding Protein 7, IBP-7, Mac25, IGF binding protein related protein-1 (IGFBP-rP1)

Accession

Q16270

GeneID

3490

Source

E.coli-derived HumanIGF-BP7 protein,Leu21-Glu282.

Molecular Weight

Approximately 26.4 kDa.

AA Sequence

SSSDTCGPCE PASCPPLPPL GCLLGETRDA CGCCPMCARG EGEPCGGGGA GRGYCAPGME CVKSRKRRKG KAGAAAGGPG VSGVCVCKSR YPVCGSDGTT YPSGCQLRAA SQRAESRGEK AITQVSKGTC EQGPSIVTPP KDIWNVTGAQ VYLSCEVIGI PTPVLIWNKV KRGHYGVQRT ELLPGDRDNL AIQTRGGPEK HEVTGWVLVS PLSKEDAGEY ECHASNSQGQ ASASAKITVV DALHEIPVKK GEGAEL

Tag

None

Physical Appearance

Sterile Filtered White lyophilized (freeze-dried) powder.

Purity

> 95 % by SDS-PAGE and HPLC analyses.

Biological Activity

Testing in Progress.

Endotoxin

< 0.1 EU per 1μg of the protein by the LAL method.

Formulation

Lyophilized from a 0.2 μm filtered concentrated solution in 20 mM Tris-HCl, pH 8.6, 150 mM NaCl.

Reconstitution

We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.

 

Shipping and Storage

The products are shipped with ice pack and can be stored at -20℃ to -80℃ for 1 year.

Recommend to aliquot the protein into smaller quantities when first used and avoid repeated freeze-thaw cycles.

 

Cautions

1. Avoid repeated freeze-thaw cycles.

2. For your safety and health, please wear lab coats and disposable gloves for operation.

3. For research use only!

Recombinant Human Insulin-like Growth Factor-Binding Protein 7 (Human IGF-BP7)_C230376

Product form

SKU: C230376E

$74.00

      • Tell a unique detail about this product

      Description

      IGF-BPs control the distribution, function and activity of IGFs in various cell tissues and body fluids. Currently, there are seven named IGF-BPs that form high affinity complexes with both IGF-I and IGF-II. IGF-BP7 is expressed in a wide range of normal human tissues, and it generally shows reduced expression in cancer cell lines of prostate, breast, colon, and lung origin.  It plays a  role in skeletal myogenesis by binding to IGF in a manner that inhibits IGF-induced differentiation of skeletal myoblasts, without affecting IGF-induced proliferation. Additionally, IGF-BP7 suppresses growth and colony formation of prostate and breast  cancer cell lines through an IGF-independent mechanism, which causes a delay in the G1 phase of the cell cycle and increased apoptosis. Recombinant Human IGF-BP7 is a 26.4 kDa protein consisting of 256 amino acid residues.

       

      Product Properties

      Synonyms

      Insulin-like Growth Factor-Binding Protein 7, IBP-7, Mac25, IGF binding protein related protein-1 (IGFBP-rP1)

      Accession

      Q16270

      GeneID

      3490

      Source

      E.coli-derived HumanIGF-BP7 protein,Leu21-Glu282.

      Molecular Weight

      Approximately 26.4 kDa.

      AA Sequence

      SSSDTCGPCE PASCPPLPPL GCLLGETRDA CGCCPMCARG EGEPCGGGGA GRGYCAPGME CVKSRKRRKG KAGAAAGGPG VSGVCVCKSR YPVCGSDGTT YPSGCQLRAA SQRAESRGEK AITQVSKGTC EQGPSIVTPP KDIWNVTGAQ VYLSCEVIGI PTPVLIWNKV KRGHYGVQRT ELLPGDRDNL AIQTRGGPEK HEVTGWVLVS PLSKEDAGEY ECHASNSQGQ ASASAKITVV DALHEIPVKK GEGAEL

      Tag

      None

      Physical Appearance

      Sterile Filtered White lyophilized (freeze-dried) powder.

      Purity

      > 95 % by SDS-PAGE and HPLC analyses.

      Biological Activity

      Testing in Progress.

      Endotoxin

      < 0.1 EU per 1μg of the protein by the LAL method.

      Formulation

      Lyophilized from a 0.2 μm filtered concentrated solution in 20 mM Tris-HCl, pH 8.6, 150 mM NaCl.

      Reconstitution

      We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.

       

      Shipping and Storage

      The products are shipped with ice pack and can be stored at -20℃ to -80℃ for 1 year.

      Recommend to aliquot the protein into smaller quantities when first used and avoid repeated freeze-thaw cycles.

       

      Cautions

      1. Avoid repeated freeze-thaw cycles.

      2. For your safety and health, please wear lab coats and disposable gloves for operation.

      3. For research use only!

      © 2024 Arcegen, Powered by Shopify

      • American Express
      • Apple Pay
      • Diners Club
      • Discover
      • Meta Pay
      • Google Pay
      • Mastercard
      • Shop Pay
      • Visa

      Login

      Forgot your password?

      Don't have an account yet?
      Create account